Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $24.00 price objective on the biotechnology company’s stock.

A number of other brokerages also recently issued reports on AVXL. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Anavex Life Sciences in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. Finally, Jones Trading cut shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Anavex Life Sciences has a consensus rating of “Hold” and a consensus price target of $22.00.

Anavex Life Sciences Stock Performance

AVXL stock opened at $4.35 on Monday. Anavex Life Sciences has a one year low of $2.86 and a one year high of $13.99. The firm has a market cap of $388.67 million, a PE ratio of -8.06 and a beta of 1.21. The firm’s 50 day moving average price is $4.29 and its 200-day moving average price is $7.02.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. Equities research analysts predict that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Anavex Life Sciences by 2.8% during the second quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock worth $18,624,000 after purchasing an additional 54,985 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Anavex Life Sciences by 6.5% in the third quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock valued at $9,229,000 after purchasing an additional 63,685 shares in the last quarter. Nwam LLC increased its stake in Anavex Life Sciences by 2.4% during the 2nd quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company’s stock worth $9,446,000 after buying an additional 24,128 shares during the period. Invesco Ltd. lifted its holdings in Anavex Life Sciences by 55.8% during the 2nd quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company’s stock worth $7,966,000 after buying an additional 309,605 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Anavex Life Sciences by 17,921.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 744,469 shares of the biotechnology company’s stock worth $2,650,000 after buying an additional 740,338 shares in the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: Q1 results beat expectations: Anavex reported EPS of ($0.06) vs. consensus ($0.10) and narrowed its net loss. Management highlighted progress on blarcamesine and a webcast was held to discuss the quarter. Read More.
• Positive Sentiment: Stronger cash runway: Cash and equivalents rose to $131.7M, giving management an estimated >3 years of runway at current burn — reduces near-term dilution risk. Read More.
• Positive Sentiment: Analyst reaffirmation and bullish target: D. Boral Capital reaffirmed a Buy and set a $24 PT (large % upside vs. current levels), likely supporting momentum and headline-driven buying interest. Read More.
• Neutral Sentiment: Regulatory engagement in U.S.: Management reported productive FDA Type C feedback and intends to submit requested Phase IIb/III data to support an NDA pathway — a constructive but multi-step process. Read More.
• Neutral Sentiment: Corporate & scientific progress: Participation in ACCESS-AD, new SVP of Neurology hire (Dr. Wolfgang Liedtke), and upcoming conference presentations/publications maintain program momentum but are longer-horizon catalysts. Read More.
• Negative Sentiment: EMA setback remains a headwind: The CHMP issued a negative opinion on the EU marketing application for blarcamesine; Anavex has requested re-examination — outcome uncertain and a material regulatory risk in Europe. Read More.
• Negative Sentiment: Ongoing losses and accumulated deficit: Net loss continues ($5.7M this quarter) and a sizable accumulated deficit remains; long-term value depends on clinical/regulatory success. Read More.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.